➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 9,051,561

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,051,561
Title:Asparaginase and treating diseases associated with asparagine dependence
Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar.RTM., an E. coli asparaginase.
Inventor(s): Durden; Donald (La Jolla, CA)
Assignee: Children\'s Hospital Los Angeles (Los Angeles, CA)
Application Number:14/348,637
Patent Claims:see list of patent claims

Details for Patent 9,051,561

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 1978-01-10 ⤷  Free Forever Trial Children\'s Hospital Los Angeles (Los Angeles, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,051,561

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2013055699 ⤷  Free Forever Trial
United States of America 2014248255 ⤷  Free Forever Trial
United States of America 2015307866 ⤷  Free Forever Trial
United States of America 9353366 ⤷  Free Forever Trial
European Patent Office 2766478 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.